TABLE 1

Baseline characteristics by age and sex

Women (n=151)Men (n=120)p-value
Age years65 (49–72)70 (60–74)0.004
WHO-FC I/II/III/IV3/18/114/16 (2%/12%/75%/11%)1/28/81/10 (1%/23%/68%/8%)0.088
BMI kg·m−226 (23–30)26 (23–29)0.274
6MWD m232 (180–349)277 (178–415)0.307
SBP mmHg129 (110–145)131 (119–148)0.114
DLCO % predicted47 (32–66)43 (30–60)0.415
eGFR mL·min−1 per 1.73 m259 (41–81)59 (43–80)0.990
NT-proBNP ng·L−11597 (590–2979)1650 (741–4239)0.729
Comorbidities
 Hypertension59 (43%)60 (57%)0.064
 Diabetes mellitus32 (23%)37 (35%)0.067
 Atrial fibrillation16 (12%)25 (24%)0.023
 Ischaemic stroke6 (4%)10 (9%)0.200
 Ischaemic heart disease13 (9%)29 (27%)0.001
Number of comorbidities
 0 comorbidities60 (44%)24 (23%)
 1 comorbidity42 (31%)27 (25%)<0.001
 ≥2 comorbidities35 (25%)55 (52%)
Haemodynamic values
 mRAP mmHg7 (4–11)7 (4–10)0.991
 mPAP mmHg48 (42–55)46 (40–52)0.131
 PAWP mmHg8 (6–11)8 (6–11)0.730
 Cardiac index L·min−1·m−22.2 (1.8–2.6)2.2 (1.8–2.5)0.904
 PVR Wood units10 (8–13)9 (6–12)0.004
PAH-targeted therapy
 Single105 (70%)98 (82%)
 Dual32 (21%)13 (11%)0.046
 Triple3 (2%)0
 No treatment11 (7%)9 (8%)
Supportive therapy
 Anticoagulants92 (61%)75 (63%)0.791
 Diuretics103 (68%)82 (68%)0.983
 Supplemental oxygen47 (31%)41 (34%)0.596

Data are presented as median (interquartile range) or n (%) unless otherwise stated. WHO-FC: World Health Organization functional class; BMI: body mass index; 6MWD: 6-min walking distance; SBP: systolic blood pressure; DLCO: diffusing capacity of the lung for carbon monoxide; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-brain natriuretic peptide; mRAP: mean right atrial pressure; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; PAH: pulmonary arterial hypertension.